NEUROCRINE BIOSCIENCES INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for NEUROCRINE BIOSCIENCES INC (NBIX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are NBIX insiders buying or selling?
In the last 12 months, NEUROCRINE BIOSCIENCES INC insiders reported 0 open-market purchases ($0) and 26 sales ($77.9M) — net selling of $77.9M. Since January 2018, Trabud has recorded 392 Form 4 filings for NBIX: 0 buys ($0) and 392 sells ($552.2M).
Source: SEC EDGAR Form 4
What stands out
- No NEUROCRINE BIOSCIENCES INC insider made an open-market purchase in the last 12 months; the 26 reported open-market sales totaled $77.9M.
Key Statistics (January 2018 – Sep 15, 2026)
Total Form 4 filings
392
SEC EDGAR
Insider filers
22
Insider buys (0)
$0
Insider sells (392)
$552.2M
Insider sentiment
Net sellingNet insider flow of $552.2M in net selling since January 2018, and $77.9M in net selling over the last 12 months.
Recent NBIX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | David W. Boyer | Chief Corp. Affairs Officer | Sale | 826 | $157.45 | $130.1K | SEC ↗ |
| Sep 15, 2026 | Matt Abernethy | Chief Financial Officer | Sale | 2.3K | $157.20 | $363.3K | SEC ↗ |
| Sep 11, 2026 | Eric Benevich | Chief Commercial Officer | Sale | 2.2K | $154.61 | $333.0K | SEC ↗ |
| Jul 30, 2026 | Leslie V Norwalk | Director | Sale | 1.3K | $182.01 | $227.5K | SEC ↗ |
| Jul 13, 2026 | Ingrid Delaet | Chief Regulatory Officer | Sale | 4.4K | $181.02 | $790.5K | SEC ↗ |
| Jul 13, 2026 | Darin Lippoldt | Chief Legal Officer | Sale | 10.0K | $179.60 | $1.8M | SEC ↗ |
| Jul 9, 2026 | Ingrid Delaet | Chief Regulatory Officer | Sale | 14.6K | $178.65 | $2.6M | SEC ↗ |
| Jun 30, 2026 | Darin Lippoldt | Chief Legal Officer | Sale | 10.0K | $170.15 | $1.7M | SEC ↗ |
| Jun 9, 2026 | SHERWIN STEPHEN A | Director | Sale | 25.0K | $165.32 | $4.1M | SEC ↗ |
| Jun 8, 2026 | Leslie V Norwalk | Director | Sale | 1.3K | $168.06 | $210.1K | SEC ↗ |
| Jun 4, 2026 | Julie Cooke | Chief Human Resources Officer | Sale | 36.9K | $156.22 | $5.8M | SEC ↗ |
| Jun 2, 2026 | Jude Onyia | Chief Scientific Officer | Sale | 11.0K | $160.25 | $1.8M | SEC ↗ |
| Jun 2, 2026 | Ingrid Delaet | Chief Regulatory Officer | Sale | 2.3K | $156.71 | $354.3K | SEC ↗ |
| May 29, 2026 | Jude Onyia | Chief Scientific Officer | Sale | 11.0K | $155.53 | $1.7M | SEC ↗ |
| May 28, 2026 | David W. Boyer | Chief Corp. Affairs Officer | Sale | 3.9K | $156.64 | $609.0K | SEC ↗ |
| May 21, 2026 | Kevin Charles Gorman | Director | Sale | 245.1K | $154.33 | $37.8M | SEC ↗ |
| May 18, 2026 | POPS RICHARD F | Director | Sale | 15.0K | $157.65 | $2.4M | SEC ↗ |
| May 14, 2026 | Leslie V Norwalk | Director | Sale | 3.8K | $155.01 | $590.6K | SEC ↗ |
| Jan 20, 2026 | Kyle Gano | Chief Executive Officer | Sale | 36.4K | $132.70 | $4.8M | SEC ↗ |
| Dec 17, 2025 | Leslie V Norwalk | Director | Sale | 6.2K | $152.78 | $945.7K | SEC ↗ |
| Dec 10, 2025 | Darin Lippoldt | Chief Legal Officer | Sale | 4.4K | $159.65 | $698.6K | SEC ↗ |
| Dec 4, 2025 | LYONS GARY A | Director | Sale | 15.0K | $152.61 | $2.3M | SEC ↗ |
| Dec 2, 2025 | Eric Benevich | Chief Commercial Officer | Sale | 6.0K | $151.74 | $905.9K | SEC ↗ |
| Nov 26, 2025 | MORROW GEORGE J | Director | Sale | 15.0K | $143.37 | $2.2M | SEC ↗ |
| Nov 6, 2025 | William H Rastetter | Director | Sale | 18.0K | $151.82 | $2.7M | SEC ↗ |
Showing the 25 most recent of 392 Form 4 filings for NEUROCRINE BIOSCIENCES INC.
Most active NBIX insiders
- Darin Lippoldt43 filings
- Eric Benevich35 filings
- Julie Cooke31 filings
- Kevin Charles Gorman28 filings
- Kyle Gano27 filings
Ask anything about NBIX insider activity
Use Trabud's AI agent to query NEUROCRINE BIOSCIENCES INC's Form 4 history in plain English — "Show me NBIX CEO purchases this year" or compare it against any other ticker.
Open the AI agentNBIX insider trading FAQ
Are NEUROCRINE BIOSCIENCES INC insiders buying or selling?
In the last 12 months, NEUROCRINE BIOSCIENCES INC insiders reported 0 open-market purchases ($0) and 26 sales ($77.9M) — net selling of $77.9M. Since January 2018, Trabud has recorded 392 Form 4 filings for NBIX: 0 buys ($0) and 392 sells ($552.2M). Over the full record that is net selling of $552.2M.
How many insiders trade NBIX stock?
22 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for NEUROCRINE BIOSCIENCES INC. The most recent filing was accepted on Sep 15, 2026.
Where does Trabud get NBIX insider trading data?
All NBIX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.